
Publication|Articles|July 24, 2024
- Ophthalmology Times: July 2024
- Volume 49
- Issue 7
What ophthalmologists need to know about neuromyelitis optica spectrum disorder
Early diagnosis of NMOSD is key to preventing disability, improving survival.
Advertisement
Advertisement
Neuromyelitis optica spectrum disorder (NMOSD) is a rare, antibody (Ab)-mediated, inflammatory autoimmune disorder of the central nervous system (CNS). Historically, the core clinical features were myelitis and optic neuritis (ON), but a better understanding of the neuroimmunology and the target (aquaporin-4 [AQP4] water channel) in NMOSD have led to expanded diagnostic criteria for NMO as a spectrum disorder. Unlike relapsing and remitting multiple sclerosis (MS), attacks of NMOSD are more severe and sometimes irreversible, leading to acute neuronal loss, blindness, and paralysis.
Related to this article

Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.

Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.

Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
Advertisement
Advertisement


